======= PAX5 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: PAX5
  * **<color #00a2e8>Official Name</color>**: paired box 5
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5079|5079]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q02548|Q02548]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=PAX5&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PAX5|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/167414|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a member of the paired box (PAX) family of transcription factors. The central feature of this gene family is a novel, highly conserved DNA-binding motif, known as the paired box. Paired box transcription factors are important regulators in early development, and alterations in the expression of their genes are thought to contribute to neoplastic transformation. This gene encodes the B-cell lineage specific activator protein that is expressed at early, but not late stages of B-cell differentiation. Its expression has also been detected in developing CNS and testis and so the encoded protein may also play a role in neural development and spermatogenesis. This gene is located at 9p13, which is involved in t(9;14)(p13;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype, and in derived large-cell lymphomas. This translocation brings the potent E-mu enhancer of the IgH gene into close proximity of the PAX5 promoter, suggesting that the deregulation of transcription of this gene contributes to the pathogenesis of these lymphomas. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2013]. 
  * **<color #00a2e8>UniProt Summary</color>**: N/A

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Pax2 C|
|PAX|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|negative regulation of histone H3-K9 methylation|
|lateral ventricle development|
|negative regulation of histone methylation|
|regulation of histone H3-K9 methylation|
|regulation of B cell receptor signaling pathway|
|ventricular system development|
|negative regulation of histone modification|
|embryonic cranial skeleton morphogenesis|
|skeletal muscle cell differentiation|
|negative regulation of chromatin organization|
|regulation of antigen receptor-mediated signaling pathway|
|regulation of histone methylation|
|cranial skeletal system development|
|embryonic skeletal system morphogenesis|
|cerebral cortex development|
|skeletal muscle tissue development|
|embryonic skeletal system development|
|skeletal muscle organ development|
|fibrillar center|
|negative regulation of chromosome organization|
|adult behavior|
|regulation of histone modification|
|pallium development|
|regulation of chromatin organization|
|skeletal system morphogenesis|
|telencephalon development|
|aging|
|striated muscle tissue development|
|embryonic organ morphogenesis|
|muscle organ development|
|muscle tissue development|
|humoral immune response|
|regulation of chromosome organization|
|negative regulation of organelle organization|
|forebrain development|
|embryonic organ development|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|muscle structure development|
|transcription by RNA polymerase II|
|skeletal system development|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|spermatogenesis|
|male gamete generation|
|embryonic morphogenesis|
|behavior|
|negative regulation of protein modification process|
|chordate embryonic development|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|embryo development ending in birth or egg hatching|
|RNA biosynthetic process|
|intracellular membrane-bounded organelle|
|gamete generation|
|negative regulation of cellular component organization|
|brain development|
|head development|
|multicellular organismal reproductive process|
|sexual reproduction|
|multicellular organism reproduction|
|negative regulation of transcription by RNA polymerase II|
|animal organ morphogenesis|
|embryo development|
|central nervous system development|
|multi-organism reproductive process|
|negative regulation of cellular protein metabolic process|
|nucleobase-containing compound biosynthetic process|
|negative regulation of protein metabolic process|
|regulation of immune response|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|regulation of organelle organization|
|organic cyclic compound biosynthetic process|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|reproductive process|
|reproduction|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|regulation of immune system process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|tissue development|
|macromolecule biosynthetic process|
|regulation of protein modification process|
|immune response|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp292|Menadione 5μM R06 exp292]]|-2.17|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM  on day4 R07 exp420]]|-1.82|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|1.73|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|1.75|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|2.07|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|2.19|
|[[:results:exp22|MLN-4924 2μM R00 exp22]]|3.15|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|3.26|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|3.4|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:m:mllt1|MLLT1]]|0.482|
|[[:human genes:g:gmppb|GMPPB]]|0.477|
|[[:human genes:t:thoc6|THOC6]]|0.474|
|[[:human genes:c:ccdc101|CCDC101]]|0.473|
|[[:human genes:t:tti1|TTI1]]|0.463|
|[[:human genes:r:rtcb|RTCB]]|0.463|
|[[:human genes:g:gnb1l|GNB1L]]|0.461|
|[[:human genes:e:eprs|EPRS]]|0.453|
|[[:human genes:e:eny2|ENY2]]|0.446|
|[[:human genes:t:telo2|TELO2]]|0.445|
|[[:human genes:r:rptor|RPTOR]]|0.444|
|[[:human genes:l:lamtor5|LAMTOR5]]|0.442|
|[[:human genes:w:wdr24|WDR24]]|0.441|
|[[:human genes:t:tti2|TTI2]]|0.439|
|[[:human genes:a:alg2|ALG2]]|0.438|
|[[:human genes:s:seh1l|SEH1L]]|0.437|
|[[:human genes:m:med16|MED16]]|0.434|
|[[:human genes:g:gtf3c2|GTF3C2]]|0.432|
|[[:human genes:f:flcn|FLCN]]|0.432|
|[[:human genes:a:aars|AARS]]|0.431|
|[[:human genes:g:gtf3c3|GTF3C3]]|0.428|
|[[:human genes:m:mapk14|MAPK14]]|0.427|
|[[:human genes:m:meaf6|MEAF6]]|0.424|
|[[:human genes:f:fnip1|FNIP1]]|0.424|
|[[:human genes:f:fbxo11|FBXO11]]|0.422|
|[[:human genes:a:alg1|ALG1]]|0.419|
|[[:human genes:v:vhl|VHL]]|0.41|
|[[:human genes:t:tceb3|TCEB3]]|0.408|
|[[:human genes:d:dpagt1|DPAGT1]]|0.407|
|[[:human genes:h:hspd1|HSPD1]]|0.405|
|[[:human genes:m:med23|MED23]]|0.404|
|[[:human genes:d:dhps|DHPS]]|0.402|
|[[:human genes:t:tle4|TLE4]]|0.401|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 1/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|1/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 996
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 9.73 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='PAX5 Expression in NALM6 Cells: 9.73'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>